Genpact Limited Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Genpact Limited on August 3, 2012, covering events occurring on August 1, 2012. The filing details a significant corporate restructuring involving a special dividend and a major share purchase transaction between private equity affiliates.
Key Financial Metrics and Transaction Details
- Special Dividend: Genpact intends to declare a special cash dividend of $2.24 per share, totaling approximately $500 million. Payment is expected prior to September 30, 2012, subject to financing.
- Share Purchase Transaction: South Asia Private Investments (an affiliate of Bain Capital) agreed to purchase approximately 68 million Genpact common shares from General Atlantic and Oak Hill Capital Partners.
- Purchase Price: The transaction price is $14.76 per share, to be paid after the special dividend.
- Total Transaction Value: Expected to be approximately $1 billion, subject to a potential reduction of up to $300 million based on financing availability.
- Financing Conditions: Financing is subject to customary conditions. If the share price is below $9.23 at closing, available financing may be reduced.
- Transaction Costs: General Atlantic and Oak Hill agreed to reimburse Genpact $17 million for out-of-pocket costs and fees.
Material Changes and Agreements
Genpact entered into several material definitive agreements to facilitate the transaction:
- Letter Agreements: Genpact waived standstill restrictions for the Purchaser and covenanted to declare the special dividend. In return, the Purchaser and Sellers agreed not to amend the Share Purchase Agreement without Genpact's consent.
- Shareholder Agreement: Upon closing, the Purchaser will be entitled to nominate four directors (provided ownership remains above 27%). The agreement includes a 30-month lock-up period for the Purchaser, with limited exceptions for public offerings if the share price exceeds $30.
- Compensation Plan Amendments: The Board amended the 2007 Omnibus Plan and ESPPs to ensure the Share Purchase does not trigger a "Change of Control." The ownership threshold for a Change of Control was raised from 25% to 50% specifically for the Purchaser.
- CEO Equity Treatment: CEO N.V. Tyagarajan's equity awards will not accelerate. Instead, he will receive an additional 30,000 restricted share units vesting on December 31, 2016, and his performance shares will remain subject to original performance goals.
- Dividend Adjustments: Outstanding equity awards will be adjusted proportionately to account for the special dividend (increasing share counts and reducing option exercise prices).
Outlook, Risks, and Contingencies
The transaction is subject to several closing conditions, including:
- Receipt of appropriate antitrust clearances.
- Accuracy of representations and warranties.
- No material adverse effect on Genpact.
- Share price condition: The transaction cannot close if Genpact shares close at $5.50 or less on any day prior to closing.
- Financing availability on satisfactory terms.
If the Share Purchase Agreement terminates, the letter agreements regarding CEO compensation and plan amendments will become void.
Key Facts for Investor Verification
- Confirm the final closing date and whether the $500 million special dividend is paid as scheduled before September 30, 2012.
- Verify the final number of shares purchased and the total transaction value, noting the potential $300 million reduction based on financing.
- Monitor the share price to ensure it does not breach the $5.50 floor condition prior to closing.
- Review the impact of the $17 million reimbursement from sellers on Genpact's immediate cash position.
- Assess the long-term governance implications of the new Shareholder Agreement, specifically the Purchaser's board representation rights and 30-month lock-up provisions.